Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which Tear-Duct surgery works better? a Head-to-Head test

NCT ID NCT07754058

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial compares two operations for primary acquired nasolacrimal duct obstruction, a condition where tears cannot drain normally from the eye into the nose, causing persistent tearing. One surgery uses a small skin incision near the inner corner of the eye, while the other goes through the nose with an endoscope and powered tools. Both procedures apply mitomycin C during surgery to reduce scarring. The study follows 60 participants for 12 months to see which approach keeps the new tear drainage opening clear and better relieves tearing symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two surgical procedures: external dacryocystorhinostomy (through a skin incision near the inner eye) and powered endoscopic dacryocystorhinostomy (through the nose with an endoscope), both with mitomycin C applied during surgery to reduce scarring.
What this could lead to
If one approach proves better, it could point to a preferred surgical method for restoring tear drainage and reducing tearing in people with blocked tear ducts.
What could go wrong
This is a single trial with 60 participants, so results may not apply to everyone. Surgery carries risks like infection, bleeding, or scarring, and the new opening may close over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jul 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Unilateral or bilateral pathological epiphora not expected to improve with conservative treatment. * Confirmed primary acquired obstruction at the level of the lacrimal sac or nasolacrimal duct, with an indication for dacryocystorhinostomy. * General health status permitting surgery under general anesthesia and participation in the 12-month follow-up. * Ability to understand the study requirements and comply with the scheduled study procedures and follow-up visits. * Written informed consent to participate in the study and undergo surgery. Exclusion Criteria: * History of previous lacrimal drainage surgery, including external, endoscopic, or laser-assisted dacryocystorhinostomy. * Acute inflammation or infection of the lacrimal drainage system, nasal cavity, or paranasal sinuses. * Suspected neoplastic lesion of the lacrimal drainage system, nasal cavity, or paranasal sinuses. * Clinically significant abnormalities of the eyelids or ocular adnexa that could contribute to epiphora. * History of eyelid surgery. * Documented hypersensitivity to mitomycin C or any medication used during the preoperative, intraoperative, or postoperative procedures. * Cognitive impairment, psychiatric disorder, or emotional instability preventing valid informed consent or adherence to the study procedures. * Inability or unwillingness to comply with the scheduled examinations and follow-up visits. * General medical condition precluding surgery under general anesthesia. * Serious life-limiting disease or another medical condition preventing completion of the 12-month follow-up. * Pregnancy or breastfeeding. * Women of childbearing potential not using an accepted method of contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary acquired nasolacrimal duct obstruction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Military Institute of Medicine - National Research Institute

    Warsaw, Masovian Voivodeship, 04-141, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.